title: Application of thymic factor "Thymalin" in complex treatment of endometrial cancer patients.
abstract: Indications have been received of cell immunity in 111 primary endometrial cancer patients in the process of complex treatment: hormonotherapy+surgery. These indices have revealed correlation with pathogenetic variants of disease. Suppression has also been registered of T-lymphocytes under the influence of complex treatment. 35 patients received thymic factor "Thymalin" as a component of complex treatment. Its positive effects on cell immunity and some clinico-morphological parameters have been registered.
authors: Division of Gynecologic Oncology, N.N. Petra Research Institute of Oncology of the USSR Ministry of Health, Leningrad.
authors: E V
authors: EV
authors: Bakhidze
authors: Bokhman JaV
mesh_terms: D000077713:17 alpha-Hydroxyprogesterone Caproate; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology; D002478:Cells, Cultured / Q000187:drug effects; D003131:Combined Modality Therapy; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000494:pharmacology; D007111:Immunity, Cellular / Q000187:drug effects / Q000502:physiology; D008875:Middle Aged; D012397:Rosette Formation; D015996:Survival Rate; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D013629:Tamoxifen / Q000494:pharmacology; D013951:Thymus Hormones / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D006908:Hydroxyprogesterones; D013951:Thymus Hormones; D013629:Tamoxifen; D000077713:17 alpha-Hydroxyprogesterone Caproate; D004958:Estradiol; C032805:thymalin